AzTrials
AzTrials

FibromyalgiaPhase 3NCT00333866

Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin In Patients With Fibromyalgia.

A Phase 3 study testing pregabalin in people with Fibromyalgia, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 74 sites in 16 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study, will compare pregabalin with placebo for the duration of 14 weeks to evaluate the efficacy and safety of pregabalin in patients with fibromyalgia. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Fibromyalgia
What is being tested?
pregabalin
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
747 participants
Where
74 sitesin 16 countries
Study dates
Jul 2006to Nov 2007
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • ACR criteria for fibromyalgia
  • A score of more or equal to 40 mm on the Pain Visual Analog Scale (VAS) and a an average score more or equal to 4 on 4 daily pain diaries

Who cannot join

  • Patients with other severe pain conditions
  • Patients with severe depression
  • Patients taking excluded medications

Trial locations and contacts

74 sites in 16 countries.

74 sites in 16 countries

Canada12 sites
  • Pfizer Investigational Site

    Bathurst, New Brunswick, E2A 4X7

  • Pfizer Investigational Site

    Drummondville, Quebec, J2B 7T1

  • Pfizer Investigational Site

    Hawkesbury, Ontario, K6A 1A1

  • Pfizer Investigational Site

    Kelowna, British Columbia, V1Y 2H4

  • Pfizer Investigational Site

    Montreal, Quebec, H3T 1E2

  • Pfizer Investigational Site

    Pointe-Claire, Quebec, H9R 3J1

  • Pfizer Investigational Site

    Québec, Quebec, G1V 3M7

  • Pfizer Investigational Site

    Sherbrooke, Quebec, J1H 1Z1

  • Pfizer Investigational Site

    Sherbrooke, Quebec, J1H 5N4

  • Pfizer Investigational Site

    St. John's, Newfoundland and Labrador, A1B 3E1

  • Pfizer Investigational Site

    Toronto, Ontario, M3K 2A7

  • Pfizer Investigational Site

    Winnipeg, Manitoba, R3A 1R9

Other trials in Canada

Germany6 sites
  • Pfizer Investigational Site

    Bad Säckingen, 79713

  • Pfizer Investigational Site

    Berlin, 10117

  • Pfizer Investigational Site

    Berlin, 14109

  • Pfizer Investigational Site

    Bonn, 53105

  • Pfizer Investigational Site

    Mannheim, 68161

  • Pfizer Investigational Site

    München, 80336

Other trials in Germany

Italy6 sites
  • Pfizer Investigational Site

    Bari, 79124

  • Pfizer Investigational Site

    Benevento, 82100

  • Pfizer Investigational Site

    Bologna, 40138

  • Pfizer Investigational Site

    Chieti Scalo, 66013

  • Pfizer Investigational Site

    Perugia, 06100

  • Pfizer Investigational Site

    Pisa

Other trials in Italy

France5 sites
  • Pfizer Investigational Site

    Clermont-Ferrand, 63003

  • Pfizer Investigational Site

    Lille, Cedex, 59037

  • Pfizer Investigational Site

    Montpellier, Cedex 5, 34295

  • Pfizer Investigational Site

    Paris, 75181

  • Pfizer Investigational Site

    Saint-Etienne, 42055

Other trials in France

Netherlands5 sites
  • Pfizer Investigational Site

    Alkmaar, 1815 JD

  • Pfizer Investigational Site

    Den Helder, 1782 GZ

  • Pfizer Investigational Site

    Leeuwarden, 8934 AD

  • Pfizer Investigational Site

    Rotterdam, 3015 GD

  • Pfizer Investigational Site

    Zwolle, 8011 JW

Other trials in Netherlands

United Kingdom5 sites
  • Pfizer Investigational Site

    Greenock, Renfrewshire, PA16 0XN

  • Pfizer Investigational Site

    London, WC1X 8LD

  • Pfizer Investigational Site

    Manchester, Greater Manchester, M6 8HD

  • Pfizer Investigational Site

    North Shields, Tyne and Wear, NE29 8NH

  • Pfizer Investigational Site

    Poole, BH12 2JB

Other trials in United Kingdom

Australia4 sites
  • Pfizer Investigational Site

    Clayton, Victoria, 3168

  • Pfizer Investigational Site

    Fitzroy, Victoria, 3065

  • Pfizer Investigational Site

    Maroochydore, Queensland, 4558

  • Pfizer Investigational Site

    Warrawong, New South Wales, 2502

Other trials in Australia

India4 sites
  • Pfizer Investigational Site

    Indore, Madhya Pradesh, 452001

  • Pfizer Investigational Site

    Lucknow, Uttar Pradesh, 226 014

  • Pfizer Investigational Site

    Ludhiana, Punjab, 141 001

  • Pfizer Investigational Site

    Ludhiana, Punjab, 141 008

Other trials in India

Mexico4 sites
  • Pfizer Investigational Site

    León, Guanajuato, 37520

  • Pfizer Investigational Site

    México, D. F., 14080

  • Pfizer Investigational Site

    Monterrey, Nuevo León, 64020

  • Pfizer Investigational Site

    San Luis Potosí City, 78240

Other trials in Mexico

Portugal4 sites
  • Pfizer Investigational Site

    Lisbon, 1050-054

  • Pfizer Investigational Site

    Lisbon, 1249-075

  • Pfizer Investigational Site

    Lisbon, 1349-019

  • Pfizer Investigational Site

    Lisbon, 1700-360

Other trials in Portugal

Spain4 sites
  • Pfizer Investigational Site

    Barcelona, 08024

  • Pfizer Investigational Site

    Barcelona, 08035

  • Pfizer Investigational Site

    Córdoba, 14004

  • Pfizer Investigational Site

    Guadalajara, 19002

Other trials in Spain

Sweden4 sites
  • Pfizer Investigational Site

    Linköping, 581 85

  • Pfizer Investigational Site

    Mölndal, 431 37

  • Pfizer Investigational Site

    Örebro, 701 85

  • Pfizer Investigational Site

    Stockholm, SE-112 81

Other trials in Sweden

South Korea3 sites
  • Pfizer Investigational Site

    Seoul, 133-792

  • Pfizer Investigational Site

    Seoul, 143-914

  • Pfizer Investigational Site

    Suwon, Kyeongki-do, 442-712

Other trials in South Korea

Switzerland3 sites
  • Pfizer Investigational Site

    Lausanne, 1011

  • Pfizer Investigational Site

    Zurich, 8063

  • Pfizer Investigational Site

    Zurich, 8091

Other trials in Switzerland

Venezuela3 sites
  • Pfizer Investigational Site

    Caracas, Distrito Federal, 1010

  • Pfizer Investigational Site

    Caracas, Distrito Federal, 1060

  • Pfizer Investigational Site

    Caracas, Miranda, 1081

Other trials in Venezuela

Denmark2 sites
  • Pfizer Investigational Site

    Frederiksberg, 2000

  • Pfizer Investigational Site

    Svendborg, 5700

Other trials in Denmark

About this study

Official title: A 14 Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia.

This study, will compare pregabalin with placebo for the duration of 14 weeks to evaluate the efficacy and safety of pregabalin in patients with fibromyalgia.

Conditions
Fibromyalgia
Being tested
pregabalin, placebo
Medical subject headings
Fibromyalgia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT00333866
Study groupRoleWhat they receive
1ExperimentalNot described
Receives: Drug: pregabalin
2ExperimentalNot described
Receives: Drug: pregabalin
3ExperimentalNot described
Receives: Drug: pregabalin
4Placebo comparatorNot described
Receives: Drug: placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in Mean Pain Score at Endpoint (Up to Week 14)

    Daily pain diary consists of 11-point NRS ranging from 0(no pain) to 10(worst possible pain). Participants rated their pain during past 24 hours, self-assessment done daily at awakening. Baseline=Last 7 available pain scores before taking study medication up to and including Day 1. Final weekly (endpoint) mean pain score is defined as the mean pain score from the last 7 pain diary entries in the study while the participant was on study medication.

    Measured: Baseline, Week 14

  2. Patient Global Impression of Change (PGIC)

    Number of participants with categorical change in overall status. PGIC: a participant-rated instrument assessing change in participant's overall status from baseline, on a scale ranging from 1 (very much improved) to 7 (very much worse).

    Measured: Week 14

Secondary outcomes (11)
  1. Change From Baseline in Mean Sleep Quality Score at Endpoint (Up to Week 14)

    Daily quality of sleep diary consists of 11-point NRS ranging from 0(best possible sleep) to 10(worst possible sleep). Participants rated their quality of sleep during past 24 hours, self-assessment done daily upon awakening. Baseline=Last 7 available scores before taking study medication up to and including Day 1. The endpoint (up to week 14) mean quality of sleep score was based on Least Squares (LS) Means using ANCOVA, with treatment group and center in the model and the baseline mean sleep score used as the covariate. Final weekly (endpoint) mean sleep quality score is defined as the mean sleep quality score from the last 7 sleep diary entries in the study while the participant was on study medication.

    Measured: Baseline, Week 14

  2. Change From Baseline in Weekly Mean Sleep Quality Score

    Daily quality of sleep diary consists of 11-point NRS ranging from 0(best possible sleep) to 10(worst possible sleep). Participants rated their quality of sleep during past 24 hours, self-assessment done daily upon awakening. Baseline=Last 7 available scores before taking study medication up to and including Day 1. The weekly mean quality of sleep score was based on LS Means using mixed model repeated measures ANCOVA, with treatment, center, week, and treatment-by-week interaction in the model and the baseline mean sleep score used as the covariate. Weekly mean sleep quality score is defined as the mean of the last 7 daily sleep diary entries.

    Measured: Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14

  3. Percentage of Participants With Optimal Sleep Assessed Using MOS-SS

    Participant-rated 12 item questionnaire assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no), as well as a 9-item overall sleep problems index. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score minus lowest possible score divided by possible raw score range*100);total score range:0-100,higher score=more disturbance.

    Measured: Baseline, Week 14

  4. Change From Baseline in Medical Outcomes Study (MOS): Sub-scales at Week 14

    Participant-rated 12 item questionnaire assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no), as well as a 9-item overall sleep problems index. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score minus lowest possible score divided by possible raw score range*100);total score range:0-100,higher score=more intensity of attribute.

    Measured: Baseline, Week 14

  5. Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Subscale Scores at Week 14

    FIQ: 20-item self-administered questionnaire designed to assess areas such as health status, progress, and outcomes in participants with fibromyalgia. 11 items related to physical functioning, other items assess pain, fatigue, stiffness, difficulty working, and symptoms of anxiousness and depression. FIQ contains 10 sub-scales scored from 0 to 10, with higher scores indicating more impairment in the subscale attribute. Total score range from 0 to 100 with higher scores indicating more impairment.

    Measured: Baseline, Week 14

  6. Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Total Scores at Week 14

    FIQ: 20-item self-administered questionnaire designed to assess areas such as health status, progress, and outcomes in participants with fibromyalgia. 11 items related to physical functioning, other items assess pain, fatigue, stiffness, difficulty working, and symptoms of anxiousness and depression. FIQ contains 10 sub-scales scored from 0 to 10, with higher scores indicating more impairment in the subscale attribute. Total score range from 0 to 100 with higher scores indicating more impairment.

    Measured: Baseline, Week 14

  7. Change From Baseline in Short Form-36 (SF-36) Health Survey at Week 14

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0- 100, where higher score represents higher level of functioning.

    Measured: Baseline, Week 14

  8. Change From Baseline in Multidimensional Assessment of Fatigue (MAF) at Week 14

    MAF is a 16-item self-administered questionnaire that yields a Global Fatigue Index (GFI), measures 4 dimensions of fatigue: degree and severity, amount of distress it causes, its timing and degree to which fatigue interferes with activities of daily living. Only 15 items are used to calculate the GFI. GFI score range from 1 (no fatigue) to 50 (severe fatigue).

    Measured: Baseline, Week 14

  9. Change From Baseline in Hospital Anxiety and Depression Scale (HADS) at Week 14

    HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.

    Measured: Baseline, Week 14

  10. Change From Baseline in Pain Visual Analogue Scale (VAS) Scores at Week 14

    Pain visual analog scale (VAS): Participants assessed the severity of their pain using a 100 mm visual analog scale (VAS). The scale ranged from 0 (no pain) to 100 (worst possible pain), measurement on a scale corresponds to the magnitude of their pain.

    Measured: Baseline, Week 14

  11. Total Daily Acetaminophen Dose

    Acetaminophen (up to 4 gram/day as needed for pain relief) was an allowable concomitant medication as a rescue therapy. The total daily acetaminophen dose taken during double-blind treatment was calculated for each participant as: (total acetaminophen dose during the study) divided by (total number of study days).

    Measured: Week 14

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Jun 2006 (estimated)
  2. Study startJul 2006
  3. Primary completionNov 2007
  4. Study completionNov 2007

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Enrolment
747 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00333866
Sponsor's protocol ID
A0081100
Status last verified
Mar 2009
First submitted
2 Jun 2006
Last updated
11 Feb 2021
Data monitoring committee
No

Publications

  • Clair A, Emir B. The safety and efficacy of pregabalin for treating subjects with fibromyalgia and moderate or severe baseline widespread pain. Curr Med Res Opin. 2016;32(3):601-9. doi: 10.1185/03007995.2015.1134463. Epub 2016 Jan 27.

    PubMed 26694975
  • Pauer L, Winkelmann A, Arsenault P, Jespersen A, Whelan L, Atkinson G, Leon T, Zeiher B; A0081100 Investigators. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol. 2011 Dec;38(12):2643-52. doi: 10.3899/jrheum.110569. Epub 2011 Oct 1.

    PubMed 21965636
  • Straube S, Moore RA, Paine J, Derry S, Phillips CJ, Hallier E, McQuay HJ. Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response. BMC Musculoskelet Disord. 2011 Jun 3;12:125. doi: 10.1186/1471-2474-12-125.

    PubMed 21639874
  • Bhadra P, Petersel D. Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials. Expert Opin Pharmacother. 2010 Dec;11(17):2805-12. doi: 10.1517/14656566.2010.525217. Epub 2010 Nov 2.

    PubMed 21039311
  • Bennett RM, Russell J, Cappelleri JC, Bushmakin AG, Zlateva G, Sadosky A. Identification of symptom and functional domains that fibromyalgia patients would like to see improved: a cluster analysis. BMC Musculoskelet Disord. 2010 Jun 28;11:134. doi: 10.1186/1471-2474-11-134.

    PubMed 20584327

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing pregabalin in people with Fibromyalgia, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 74 sites in 16 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 74 sites in Canada, Germany, Italy, France, Netherlands and 11 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 13 May 2009). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Mean Pain Score at Endpoint (Up to Week 14) (time frame: Baseline, Week 14). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00333866, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Feb 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in